Trump hits the manufacturer Ozmpic. Danish Novo Nordisk may be in trouble

2025-05-16 18:38
publication
2025-05-16 18:38
The decree of US President Donald Trump announcing to reduce the prices of drugs from Europe is a challenge for the Danish pharmaceutical industry – said on Friday the Minister of Industry Dania Morten Boedskov.


“There is no doubt that Trump's announcement regarding pharmaceutical products is the next step in the wrong direction,” emphasized Boedskov. He added that “it creates even greater uncertainty” and “creates new barriers for Danish trade.”
In connection with the situation, the Minister of Industry announced consultations with representatives of the largest Danish pharmaceutical companies.
President Trump during a Monday press conference directly referred to his opinion too high in the USA medicine for obesity ozempiic, produced by the Danish group Novo Nordisk.
On Friday, Novo Nordisk announced parting with the current president Lars Fruergaard Joergensen. The Danish media called this message surprising, although they reminded of the recently falling company's stock exchange rate and worse financial results. 59-year-old Joergensen, son of a farmer, managed the company since 2017 and was considered the father of the success of the Danish producer of innovative drugs with which he was associated with all his professional life.
Minister Boedskov expressed appreciation for Joergensen's merits, but he did not want to refer to his release. In Denmark, the pharmaceutical industry and drug exports are the driving force of the economy, which allows you to finance the expenditure of the guardianship state.
According to Trump signed by Trump on Monday, other elements of the President's President's plan to reduce the prices of drugs assume, among others Determining medicines at the level of other developed countries by means of appropriate regulations, as well as increasing the import of medical agents from abroad. According to the decree, the company will have 30 days to make progress to reduce the prices of medicines in the US, and if they do not do it, appropriate regulations are to be introduced to bring to this. (PAP)
Zys/ AP/
arch.




